CASI Pharmaceuticals Inc - Company Profile

Powered by

All the data and insights you need on CASI Pharmaceuticals Inc in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date CASI Pharmaceuticals Inc Strategy Report

  • Understand CASI Pharmaceuticals Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

CASI Pharmaceuticals Inc: Overview

Select Item

CASI Pharmaceuticals Inc (CASI) is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapies for treating cancer and other unmet medical needs. The company’s product EVOMELA (melphalan for injection) an intravenous formulation for the treatment of multiple myeloma. It’s pipeline product portfolio includes CID-103 for treatment of multiple myeloma; CNTC 19 for hematological malignancies; ZEVALIN for treatment of relapsed/refractory, low-grade B-cell non-Hodgkin’s lymphoma (NHL); MARQIBO for treatment of Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL); BI-1206 for non-hodgkin's lymphoma and solid tumors; CB-5339 AML/MDS and solid tumors; Octreotide LAI for treatment of acromegaly and symptoms associated with neuroendocrine tumors. The company operates its subsidiaries in the US and China and a research and development center in Beijing, China. CASI is headquartered in Rockville, Maryland, the US.

 Gain a 360-degree view of CASI Pharmaceuticals Inc and make more informed decisions for your business Gain a 360-degree view of CASI Pharmaceuticals Inc and make more informed decisions for your business Find out more
Headquarters China
Address 9620 Medical Center Drive, Suite 300, Beijing, 100025
Website www.casipharmaceuticals.com
Telephone 86 10 65618789
No of Employees 176
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange CASI (NASD)
Revenue (2022) $33.9M -21.4% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 24.9% (2022 vs 2021)
Market Cap* $34.8M
Net Profit Margin (2022) XYZ 4.5% (2022 vs 2021)
* As of and is in US$
View CASI Pharmaceuticals Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

CASI Pharmaceuticals Inc premium industry data and analytics

40+

Clinical Trials

Determine CASI Pharmaceuticals Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

20+

Pipeline Drugs

Identify which of CASI Pharmaceuticals Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

18+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for CASI Pharmaceuticals Inc’s relevant decision makers and contact details.

13+

Catalyst Calendar

Proactively evaluate CASI Pharmaceuticals Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

7

Marketed Drugs

Understand CASI Pharmaceuticals Inc’s commercialized product portfolio to stay one step ahead of the market.

3

Sales & Consensus Forecasts

Understand the current and future drug revenue for CASI Pharmaceuticals Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

2

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on CASI Pharmaceuticals Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products
EVOMELA – for multiple myeloma
Pipeline
BI-1206-non-Hodgkin’s lymphoma and solid tumors
XYZ
XYZ
XYZ
Understand CASI Pharmaceuticals Inc portfolio and identify potential areas for collaboration Understand CASI Pharmaceuticals Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Contracts/Agreements In August, the company entered into an agreement with Mundipharma International Corporation Limited for the commercialization of FOLOTYN.
2023 Official Trials/Tests In January, the company announced the approval of Clinical Trial Application for CB-5339 by China National Medical Products Administration.
2022 Regulatory Approval In December, the company announced the acceptance of New Drug Application for CNCT19 by China National Medical Products Administration.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters CASI Pharmaceuticals Inc Hualan Biological Engineering Inc Viva Biotech Holdings Fennec Pharmaceuticals Inc Cardiff Oncology Inc
Headquarters China China China United States of America United States of America
City Beijing Xinxiang Shanghai Research Triangle Park San Diego
State/Province Beijing Henan Shanghai North Carolina California
No. of Employees 176 3,709 2,271 36 31
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Wei-Wu He, Ph.D. Chairman; Chief Executive Officer Executive Board 2019 58
Alexander A. Zukiwski, M.D. Chief Medical Officer Senior Management 2017 64
Fuqiang Zhang Chief Commercial Officer Senior Management 2021 54
Chunhua Wang Chief Operating Officer - CASI Pharmaceuticals (Beijing) Co Senior Management 2018 -
Larry Zhang Principal Financial Officer; President Senior Management 2019 63
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into CASI Pharmaceuticals Inc key executives to enhance your sales strategy Gain insight into CASI Pharmaceuticals Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward